Compare LCID & ACAD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | LCID | ACAD |
|---|---|---|
| Founded | 2007 | 1993 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Auto Manufacturing | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.7B | 3.8B |
| IPO Year | 2020 | 2000 |
| Metric | LCID | ACAD |
|---|---|---|
| Price | $5.71 | $22.09 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 7 | 22 |
| Target Price | $15.71 | ★ $30.55 |
| AVG Volume (30 Days) | ★ 16.9M | 1.4M |
| Earning Date | 05-05-2026 | 05-06-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 69.12 |
| EPS | N/A | ★ 2.30 |
| Revenue | $595,271,000.00 | ★ $726,437,000.00 |
| Revenue This Year | $71.67 | $18.80 |
| Revenue Next Year | $89.72 | $11.70 |
| P/E Ratio | ★ N/A | $9.87 |
| Revenue Growth | N/A | ★ 40.45 |
| 52 Week Low | $1.97 | $14.20 |
| 52 Week High | $25.22 | $28.35 |
| Indicator | LCID | ACAD |
|---|---|---|
| Relative Strength Index (RSI) | 22.73 | 50.68 |
| Support Level | $2.11 | $21.51 |
| Resistance Level | $10.97 | $22.97 |
| Average True Range (ATR) | 0.58 | 0.66 |
| MACD | -0.19 | 0.08 |
| Stochastic Oscillator | 1.56 | 65.03 |
Lucid Group Inc is a technology and automotive company. It develops the next generation of electric vehicle (EV) technologies. It offers its own geographically distributed retail and service locations and through direct-to-consumer online and retail sales. It also boasts a product roadmap of future vehicle programs and technologies. It focuses on in-house hardware and software innovation, vertical integration, and a clean-sheet approach to engineering and design led to the development of the Lucid Air. The Lucid Air is a luxury sedan that redefines both the luxury car segment and the EV space. Its geographic segments include North America, the Middle East, and Other International.
Acadia Pharmaceuticals Inc is a biopharmaceutical company focused on turning scientific promise to makes a difference for underserved neurological and rare disease communities around the world. It has two core franchises in neurological and rare diseases. Its neurological disease is anchored by the commercial product NUPLAZID (pimavanserin), which is the first and only drug approved by the U.S. (FDA) for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis (PDP). Its rare disease is anchored by the commercial product DAYBUE, which is the first and only drug approved for the treatment of Rett syndrome. Its clinical-stage development efforts are focused on Alzheimer's disease psychosis, Lewy Body Dementia psychosis, and multiple other programs.